IMU.AXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (26 4月 2024 @ 15:10):

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia...

Stats
本日の出来高	17.07M
平均出来高	15.87M
時価総額	578.26M
EPS	$0 ( 2024-03-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.90
ATR14	$0 (0.00%)

ボリューム相関

長: -0.12 (neutral)

短: -0.69 (moderate negative)

Signal:(45.931) Neutral

Imugene Ltd 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Imugene Ltd 相関 - 通貨/商品

0.00
( neutral )

Imugene Ltd 財務諸表

Annual	2023
収益:	$11.78M
総利益:	$9.57M (81.29 %)
EPS:	$-0.00600

FY	2023
収益:	$11.78M
総利益:	$9.57M (81.29 %)
EPS:	$-0.00600

FY	2022
収益:	$12.97M
総利益:	$10.56M (81.44 %)
EPS:	$-0.00670

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.00453

Financial Reports:

No articles found.

Imugene Ltd

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.